
Exelixis (EXEL) Stock Forecast & Price Target
Exelixis (EXEL) Analyst Ratings
Bulls say
Exelixis Inc. is demonstrating strong momentum with its Cabometyx product, which has seen a notable increase in market share, commanding 46% in the TRx market for renal cell carcinoma (RCC) and achieving a 15% year-over-year growth in TRx volume. The company is strategically expanding its gastrointestinal sales team to enhance its market presence and capitalize on the positive demand for Cabometyx, while also preparing for the launch of the promising drug zanzalintinib for colorectal cancer (CRC). Furthermore, Exelixis maintains a robust balance sheet and sustainable profitability, which sets it apart in the biopharmaceutical sector and supports its increasing sales forecasts through fiscal years 2026 to 2028.
Bears say
Exelixis Inc. has experienced a decline in its gross-to-net (GTN) percentage, decreasing from 30.2% in 3Q25 to 28.5% in 4Q25, primarily due to a drop in PHS/340B volume, which raises concerns about revenue stability. Despite achieving $545 million in Cabometyx sales for 4Q25, this figure fell short of both company and consensus estimates, indicating challenges in meeting growth expectations amid a competitive landscape in renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Additionally, various risks, including commercial vulnerabilities related to Cabometyx and potential generic competition, along with uncertainties surrounding ongoing clinical trials, contribute to an overall negative outlook on Exelixis's stock performance.
This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.
Exelixis (EXEL) Analyst Forecast & Price Prediction
Start investing in Exelixis (EXEL)
Order type
Buy in
Order amount
Est. shares
0 shares